11 Hopefully, it will help to use TDM optimally from a scientific, clinical, and economic point of view. Selected abbrewiations and acronyms CYP cytochrome P-450 GC gas chromatography HPLC high-performance liquid chromatography LOD limit of detection LOQ limit of quantification PM poor metabolizer SSRI selective selleck compound serotonin reuptake inhibitor TDM therapeutic drug monitoring UM ultrarapid metabolizer Notes *This

review takes into consideration antidepressant agents those currently available in Switzerland and Germany, and therefore does not claim to be exhaustive. This article is a modified version of an article published in the journal Pharmacopsychiatry Inhibitors,research,lifescience,medical in December 2004: Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37:243-265. It is published here with the kind permission of the

publishers Georg Thieme Verlag KG, Stuttgart, Germany.
Whatever the antidepressant drug prescribed, 30%1 to Inhibitors,research,lifescience,medical 50%2 of adult Inhibitors,research,lifescience,medical patients with major depression fail to respond to adequate first-line treatment, defined as a dose In the therapeutic range given for an adequate duration, ie, 4 to 6 weeks.3 In clinical practice, when a patient responds Insufficiently to an initial antidepressant dose, several options are available, such as temporizing, increasing the dose, switching to another antidepressant, or combining several drugs.4 A survey by Fredman et al5 of attendees at a psychopharmacology course showed that 80% or Inhibitors,research,lifescience,medical more Indicated that their first choice would be to raise the selective serotonin reuptake Inhibitor (SSRI) dose for a hypothetical patient with minimal response after 4 weeks, or partial response after 8 weeks, of adequate treatment, Inhibitors,research,lifescience,medical Ie, fluoxetine 20 mg/day, sertraline 100 mg/day, or paroxetine 20 mg/day. For a patient with no response

after 8 weeks of adequate SSRI treatment, a switch to a non-SSRI drug was the first and preferred strategy. Hirschfeld et al4 advocated switching, combination therapy, or augmentation therapy after 4 weeks for patients who fall to respond Anacetrapib at an adequate dosage of SSRI (Ie, <25% decrease In the Hamilton Rating Scale for Depression [HAMD] or Montgomery and Åsberg Depression Rating Scale [MADRS] score). For those patients who achieve a partial response on firstline therapy (ie, 25% to 50% decrease In HAMD or MADRS score), they proposed that treatment should be continued for 6 to 8 weeks at an adequate dose before considering a change In therapeutic management.4 An Important question Is whether the frequently applied strategy of Increasing the dose of antidepressant is justified. The Issue Is of fundamental and clinical relevance.